CV Therapeutics ends co-promotion of Aceon

CV Therapeutics said it would finish the promotion of high blood pressure drug Aceon over the next few weeks.

There are no financial commitments for either company related to the termination of the co-promotion agreement. CV Therapeutics does not expect to recognize further revenues from Aceon.

Aceon is indicated for the treatment of coronary artery disease and hypertension.

CV Therapeutics said they would now focus its promotional efforts on the product Ranexa. Ranexa is an approved product indicated for the treatment of chronic angina.

CV Therapeutics is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of small molecule drugs for the treatment of cardiovascular diseases.